#174 Lp(a) and ASCVD Risk: 5 Pearls Segment

What does Lipoprotein(a) tell us that a standard lipid panel doesn’t? Should we be testing everyone for it? Dive into the genetics, clinical implications, and evolving management strategies for Lp(a). Learn how to interpret results, counsel patients, and navigate topics with limited data like aspirin and PCSK9 inhibitors in treatment.🔹 Sponsor: Freed is an AI scribe that listens and writes your note in < 30 seconds. Freed learns your style over time and is HIPAA compliant! Use the code CORE50 to get 50% off your first month with Freed🔹 Transcript and Show NotesTimestamps:(02:17) | Pearl 1: What makes Lp(a) unique? How does it raise ASCVD risk?(10:32) | Pearl 2: Who should be tested for Lp(a)? When and why?(16:54) | Pearl 3: Understanding and interpreting Lp(a) levels(24:04) | Pearl 4: How does an elevated Lp(a) affect management?(37:05)| Pearl 5: The role of aspirin and PCSK9 inhibitors in Lp(a)Tags: CoreIM, Internal Medicine, Primary Care, Preventive Cardiology, Atherosclerosis, Lipid Management, Medical Education, IMCore, Physician Assistant, Nurse Practitioner, Medical StudentFind the best disability insurance for you: https://www.patternlife.com/disability-insurance?campid=497840Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy